JNJ
Johnson & Johnson · Healthcare · Drug Manufacturers - General
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 12.70M | $3.29B | n/a | n/a |
| Q2 2026 | 183 | +1 | 1.45B | $367.17B | +5 | −3 |
| Q1 2026 | 184 | 0 | 1.43B | $348.29B | +4 | −5 |
| Q4 2025 | 183 | 0 | 1.52B | $314.40B | +2 | −1 |
| Q3 2025 | 28 | 0 | 887.20M | $164.46B | n/a | −1 |
| Q2 2025 | 26 | +1 | 740.96M | $113.15B | +1 | n/a |
| Q1 2025 | 22 | -1 | 281.15M | $46.60B | n/a | −1 |
| Q4 2024 | 23 | +3 | 290.64M | $42.01B | +3 | n/a |
| Q3 2024 | 19 | -2 | 157.55M | $25.50B | n/a | −2 |
| Q2 2024 | 21 | n/a | 161.11M | $23.53B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Ninety One UK Ltd | 6.49M | -4.2% | $1.72B | 3.8% | ▼ Trim | 4 | SEC ↗ |
| 2 | Assenagon Asset Management S.A. | 2.99M | -22.9% | $791.76M | 0.8% | ▼ Trim | 4 | SEC ↗ |
| 3 | Wealth Enhancement Advisory… | 1.98M | +8.2% | $464.45M | 0.7% | ▲ Add | 4 | SEC ↗ |
| 4 | TD Waterhouse Canada Inc. | 1.23M | +22.6% | $319.18M | 0.8% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 136.10K shares, $33,268 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 11.07K sh · $3.04M
Officer · 22.53K sh · $6.19M
Officer · 15.00K sh · $3.95M
Officer, Director · 102.31K sh · $26.70M
Officer, Director · 20.98K sh · $5.50M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology